Company
Headquarters: York, United Kingdom
Employees: 37
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Aptamer Group plc provides binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, and internationally. The company offers Optimer platform that enables the discovery and development of oligonucleotide binders; custom development services for oligonucleotide-based aptamer and Optimer binders; solutions to bioprocessing, diagnostic, and pharmaceutical scientists; and contract research services in the field of therapeutics. It serves pharma companies, diagnostic development companies, and research institutes. Aptamer Group plc was founded in 2008 and is headquartered in York, the United Kingdom.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £1.0 M |
| EBITDA | £-4,209,000 |
| Gross Profit TTM | £359,000 |
| Profit Margin | 20.49% |
| Operating Margin | -628.19% |
| Quarterly Revenue Growth | -70.60% |
Aptamer Group plc has the following listings and related stock indices.
Stock: LSE: APTA